Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1349 (LINC01349) is a non-protein-coding RNA gene classified as a lincRNA[1]. LincRNAs are transcripts longer than 200 nucleotides and fall under the broader category of long non-coding RNAs (lncRNAs)[7][9]. They do not overlap with protein-coding genes and are generally implicated in the regulation of gene expression at transcriptional and epigenetic levels, although the specific biological role or disease association of LINC01349 is not described in the available literature or genetic resources as of 2024[1][7][9]. Most lincRNAs are not considered direct therapeutic targets but are the subject of research for their regulatory functions and potential as biomarkers or modifiers of disease pathways[5][9]. There is no evidence that LINC01349 is directly involved in signaling, cell proliferation, apoptosis, or any major disease, nor is it a target for any approved drugs as of September 2025[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1349 (LINC01349).